Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Reversed Potts Shunt Outcome in Suprasystemic Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

Author(s): Brian Mendel*, Christianto Christianto, Phoniex Angellia, Indra Holiyono, Radityo Prakoso and Sisca Natalia Siagian

Volume 18, Issue 6, 2022

Published on: 13 July, 2022

Article ID: e090522204486 Pages: 9

DOI: 10.2174/1573403X18666220509203335

Price: $65

Abstract

Background: Reversed Potts shunt has been a prospective approach to treat suprasystemic pulmonary hypertension, particularly when medication treatment fails to reduce right ventricular afterload.

Objective: This meta-analysis aims to review the clinical, laboratory, and hemodynamic parameters after a reversed Potts shunt in suprasystemic pulmonary hypertension patients.

Methods: Six electronic databases were searched from the date of inception to August 2021, where the obtained studies were evaluated according to the PRISMA statement. The effects of shunt creation were evaluated by comparing preprocedural to postprocedural or follow-up parameters, expressed as a mean difference of 99% confidence interval. Quality assessment was conducted using the STROBE statement.

Results: Seven studies suited the inclusion criteria which were included in this article. A reduction in upper and lower limb oxygen saturation [Upper limb: St. Mean difference -0.55, 99% CI -1.25 to 0.15; P=0.04; I2=6%. Lower limb: St. Mean difference –4.45, 99% CI –7.37 to –1.52; P<0.00001; I2=65%]. Reversed Potts shunt was shown to improve WHO functional class, 6-minute walk distance, NTpro-BNP level, and hemodynamic parameters including tricuspid annular plane systolic excursion, interventricular septal curvature, and end-diastolic right ventricle/left ventricle ratio.

Conclusion: Reversed Potts shunt cannot be said to be relatively safe, although it allows improvement in the clinical and functional status in patients with suprasystemic PAH. Reversed Potts shunt procedure may be the last resort for drug-resistant pulmonary hypertension as it is considered a high-risk procedure performed on patients with extremely poor conditions.

Keywords: Outcome, pulmonary arterial hypertension, reversed Potts shunt, suprasystemic, PRISMA, pulmonary vascular resistance, pulmonary artery coupling.

Graphical Abstract

[1]
Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53(1): 1801916.
[http://dx.doi.org/10.1183/13993003.01916-2018] [PMID: 30545978]
[2]
Baruteau AE, Belli E, Boudjemline Y, et al. Palliative potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: Updated data from the first 24 patients. Eur J Cardiothorac Surg 2015; 47(3): e105-10.
[http://dx.doi.org/10.1093/ejcts/ezu445] [PMID: 25475943]
[3]
Boudjemline Y, Sizarov A, Malekzadeh-Milani S, et al. Safety and feasibility of the transcatheter approach to create a reverse Potts shunt in children with idiopathic pulmonary arterial hypertension. Can J Cardiol 2017; 33(9): 1188-96.
[http://dx.doi.org/10.1016/j.cjca.2017.06.004] [PMID: 28843329]
[4]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[5]
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014; 12(12): 1495-9.
[http://dx.doi.org/10.1016/j.ijsu.2014.07.013] [PMID: 25046131]
[6]
Manager R. (RevMan) [Computer program] The Cochrane Collaboration. 2020.
[7]
Aggarwal M, Grady RM, Choudhry S, Anwar S, Eghtesady P, Singh GK. Potts shunt improves right ventricular function and coupling with pulmonary circulation in children with suprasystemic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2018; 11(12): e007964.
[http://dx.doi.org/10.1161/CIRCIMAGING.118.007964] [PMID: 30558504]
[8]
Gorbachevsky SV, Shmalts AA, Barishnikova IY, Zaets SB. Potts shunt in children with pulmonary arterial hypertension: Institutional experience. Interact Cardiovasc Thorac Surg 2017; 25(4): 595-9.
[http://dx.doi.org/10.1093/icvts/ivx209] [PMID: 28679172]
[9]
Kirkpatrick EC, Handler SS, Foerster S, Gudausky T, Tillman K, Mitchell M. Single center experience with the Potts shunt in severe pulmonary arterial hypertension. Prog Pediatr Cardiol 2018; 48: 111-5.
[http://dx.doi.org/10.1016/j.ppedcard.2017.12.002]
[10]
Grady RM, Eghtesady P. Potts shunt and pediatric pulmonary hypertension: What we have learned. Ann Thorac Surg 2016; 101(4): 1539-43.
[http://dx.doi.org/10.1016/j.athoracsur.2015.08.068] [PMID: 26518375]
[11]
Bobhate P, Mohanty SR, Tailor K, et al. Potts shunt as an effective palliation for patients with end stage pulmonary arterial hypertension. Indian Heart J 2021; 73(2): 196-204.
[http://dx.doi.org/10.1016/j.ihj.2021.01.007] [PMID: 33865518]
[12]
Zelt JGE, Chaudhary KR, Cadete VJ, Mielniczuk LM, Stewart DJ. Medical therapy for heart failure associated with pulmonary hypertension. Circ Res 2019; 124(11): 1551-67.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.313650] [PMID: 31120820]
[13]
Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141(8): 678-93.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022362] [PMID: 32091921]
[14]
Schranz D, Akintuerk H, Voelkel NF. ‘End-stage’ heart failure therapy: Potential lessons from congenital heart disease: From pulmonary artery banding and interatrial communication to parallel circulation. Heart 2017; 103(4): 262-7.
[http://dx.doi.org/10.1136/heartjnl-2015-309110] [PMID: 28011759]
[15]
Blanc J, Vouhé P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 2004; 350(6): 623-3.
[http://dx.doi.org/10.1056/NEJM200402053500623] [PMID: 14762197]
[16]
Santos M, Furtado I, Goncalves F, Carvalho L, Reis A. Prognostic impact of oxygen saturation during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2016; 48 (Suppl. 60): PA2405.
[17]
Delhaas T, Koeken Y, Latus H, Apitz C, Schranz D. Potts shunt to be preferred above atrial septostomy in pediatric pulmonary arterial hypertension patients: A modeling study. Front Physiol 2018; 9(SEP): 1252.
[http://dx.doi.org/10.3389/fphys.2018.01252] [PMID: 30246808]
[18]
Latus H, Apitz C, Moysich A, et al. Creation of a functional Potts shunt by stenting the persistent arterial duct in newborns and infants with suprasystemic pulmonary hypertension of various etiologies. J Heart Lung Transplant 2014; 33(5): 542-6.
[http://dx.doi.org/10.1016/j.healun.2014.01.860] [PMID: 24630407]
[19]
Corris P, Degano B. Severe pulmonary arterial hypertension: Treatment options and the bridge to transplantation. Eur Respir Rev 2014; 23(134): 488-97.
[http://dx.doi.org/10.1183/09059180.00007214] [PMID: 25445947]
[20]
Ivy D. Pulmonary hypertension in children. Cardiol Clin 2016; 34(3): 451-72.
[http://dx.doi.org/10.1016/j.ccl.2016.04.005] [PMID: 27443141]
[21]
Lammers AE, Apitz C, Zartner P, Hager A, Dubowy KO, Hansmann G. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart 2016; 102 (Suppl. 2): ii1-ii13.
[http://dx.doi.org/10.1136/heartjnl-2015-307792] [PMID: 27053692]
[22]
Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34(6): 1219-63.
[http://dx.doi.org/10.1183/09031936.00139009] [PMID: 19749199]
[23]
Gorbachevkiy SV, Shmal’ts AA, Belkina MV, Grenaderov MA, Baryshnikova IY, Pursanov MG. Potts shunt in children with pulmonary hypertension: 7 operations in one clinic and review of world experience. Det Bolezn Serdtsa i Sosudov 2016; 13(4): 189-98.
[24]
Baruteau AE, Serraf A, Lévy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: Long-term results. Ann Thorac Surg 2012; 94(3): 817-24.
[http://dx.doi.org/10.1016/j.athoracsur.2012.03.099] [PMID: 22704329]
[25]
Deboeck G, Niset G, Vachiery JL, Moraine JJ, Naeije R. Physiological response to the six-minute walk test in pulmonary arterial hypertension. Eur Respir J 2005; 26(4): 667-72.
[http://dx.doi.org/10.1183/09031936.05.00031505] [PMID: 16204599]
[26]
Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: How far is enough? Am J Respir Crit Care Med 2012; 186(5): 396-7.
[http://dx.doi.org/10.1164/rccm.201206-1137ED] [PMID: 22942342]
[27]
Demir R, Küçükoğlu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol 2015; 15(3): 249-54.
[http://dx.doi.org/10.5152/akd.2015.5834] [PMID: 25880178]
[28]
Souza R, Channick RN, Delcroix M, et al. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One 2018; 13(3): e0193226.
[http://dx.doi.org/10.1371/journal.pone.0193226] [PMID: 29590122]
[29]
Berghaus TM, Kutsch J, Faul C, von Scheidt W, Schwaiblmair M. The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: Results from a cohort study. BMC Pulm Med 2017; 17(1): 167.
[http://dx.doi.org/10.1186/s12890-017-0521-4] [PMID: 29202745]
[30]
Chin KM, Rubin LJ, Channick R, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Circulation 2019; 139(21): 2440-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039360] [PMID: 30982349]
[31]
Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: Biomarker and potential therapeutic agent. Drug Des Devel Ther 2009; 3: 269-87.
[PMID: 20054445]
[32]
Badesch DB, Champion HC, Gomez Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1) (Suppl.): S55-66.
[http://dx.doi.org/10.1016/j.jacc.2009.04.011] [PMID: 19555859]
[33]
Wu VCC, Takeuchi M. Echocardiographic assessment of right ventricular systolic function. Cardiovasc Diagn Ther 2018; 8(1): 70-9.
[http://dx.doi.org/10.21037/cdt.2017.06.05] [PMID: 29541612]
[34]
Haddad F, Guihaire J, Skhiri M, et al. Septal curvature is marker of hemodynamic, anatomical, and electromechanical ventricular interdependence in patients with pulmonary arterial hypertension. Echocardiography 2014; 31(6): 699-707.
[http://dx.doi.org/10.1111/echo.12468] [PMID: 24372843]
[35]
Lancaster TS, Shahanavaz S, Balzer DT, Sweet SC, Grady RM, Eghtesady P. Midterm outcomes of the potts shunt for pediatric pulmonary hypertension, with comparison to lung transplant. J Thorac Cardiovasc Surg 2021; 161(3): 1139-48.
[http://dx.doi.org/10.1016/j.jtcvs.2020.10.163] [PMID: 33454101]

Rights & Permissions Print Cite
Article Metrics
42
2
© 2024 Bentham Science Publishers | Privacy Policy